CRISPR Therapies, Base Editing and Approvals — 2026-10-12
CRISPR Therapeutics is set to present pivotal late-breaking Phase 1b data for its in vivo gene editing therapy, CTX310, at the American Heart Association Scientific Sessions this week. Meanwhile, analysts are weighing near-term catalysts for CRISPR Therapeutics stock, with Citi projecting significant upside potential based on upcoming clinical readouts and market positioning.
CRISPR Therapies, Base Editing and Approvals — 2026-10-12
Top developments
CRISPR Therapeutics to Present In Vivo CTX310 Data at AHA 2026
On October 8, 2026, CRISPR Therapeutics announced it will present late-breaking clinical data from the Phase 1b trial of CTX310®, its investigational CRISPR/Cas9 in vivo gene editing therapy targeting angiopoietin-related protein 3 (ANGPTL3). The presentation, scheduled for the American Heart Association (AHA) Scientific Sessions 2026 (October 6–9), focuses on patients with severe hypertriglyceridemia. This marks a critical step for in vivo editing platforms, moving beyond ex-vivo successes like Casgevy to demonstrate systemic efficacy and safety in lipid disorders.
Citi Analysts See 60% Upside for CRISPR Therapeutics
In a report published on October 9, 2026, Citi analysts highlighted three key factors driving potential gains for CRISPR Therapeutics, projecting a 60% upside for the stock. The analysis suggests that while the company has faced a rocky 2026, the firming up of near-term catalysts—particularly the upcoming data reads for its pipeline—could significantly revalue the company. This sentiment contrasts with earlier skepticism about whether the market is underestimating the company's key catalysts coming by the end of 2026.
Post-Exa-Cel Era: Next Wave of Gene Editing Strategies
As of October 9, 2026, industry commentary is focusing on the strategic shift following the approval of exa-cel (Casgevy). CGTlive® reports that the approval of the first gene-editing therapy is heralding a new era in developing gene-editing strategies, with a focus on expanding indications and improving delivery mechanisms. This discussion contextualizes the current wave of trials, including Intellia’s progress with lonvo-z for hereditary angioedema, which showed dramatic reduction in swelling attacks in Phase 3 trials earlier this year.
Local view
No recent local-language media coverage specific to gene-editing approvals or trials was identified within the past 7 days that provides distinct stakeholder perspectives beyond global financial reporting.
Context & numbers
- Casgevy List Price: $2.2 million per patient.
- Lyfgenia List Price: $3.1 million per patient.
- Market Cap Sentiment: Citi's projection implies a significant valuation gap if CTX310 and other pipeline assets succeed.
On the radar
- AHA Scientific Sessions Data Release: The full details of the CTX310 Phase 1b trial results were embargoed until the oral session at 8 a.m. CST during the AHA meetings (Oct 6–9, 2026). Investors should look for detailed safety profiles and efficacy figures now that the conference has concluded.
- FDA Guidance Updates: The FDA continues to refine guidance on "Human Gene Therapy Products Incorporating Human Genome Editing," with draft guidance from June 2026 still influencing clinical hold decisions and approval pathways.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
